The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a more substantial loss in body weight and enhance metabolic markers, particular